Integrated Global Biosimilars Business | Reliance Life Sciences - LifeSciences
Products
- AbcixiRel® (Abciximab)
- AdaliRel® (Adalimumab)
- BevaciRel® (Bevacizumab)
- ChorioRel® (r-hCG)
- DarbeRel® (Darbepoetin)
- EtanerRel® (Etanercept)
- FostiRel® (FSH)
- Infimab® (Infliximab)
- MIRel® (Reteplase)
- OmaliRel™ (Omalizumab)
- Peg-ReliGrast® (Peg-GCSF)
- RanizuRel™ (Ranibizumab)
- ReliBeta® (Interferon beta-1a)
- ReliFeron® (Interferon α)
- ReliGrast® (GCSF)
- ReliPoietin® (Erythropoietin)
- RituxiRel® (Rituximab)
- SomatoRel® (r-hGH)
- TenecteRel® (Tenecteplase)
- TrastuRel® (Trastuzumab)
- DenosuRel™ (Denosumab)
- DenOsteoRel™ (Denosumab)
Business-Biosimilars
Biosimilars
Reliance Life Sciences is building an integrated and global biosimilars business.
The company currently markets biosimilars in India and overseas markets.
These products are manufactured in-house in two commercial scale facilities for recombinant proteins and monoclonal antibodies (mammalian and microbial cell culture and fill finish for vials and syringes).